How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s
Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans.
The Phase III EMBARK study has fallen short on its primary endpoint – but Sarepta believes the trial has otherwise produced robust data, and believes a full US approval is justified.
The first clinical trial results for Roche’s brain shuttle technology in Alzheimer’s patients showed that trontinemab cleared more amyloid and at a faster pace than its failed predecessor gantenerumab.